B Alt-Epping1, A-L Haas2, M Jansky3, F Nauck3. 1. Klinik für Palliativmedizin, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland. bernd.alt-epping@med.uni-goettingen.de. 2. Medizinische Fakultät, Universitätsmedizin Göttingen, Göttingen, Deutschland. 3. Klinik für Palliativmedizin, Universitätsmedizin Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland.
Abstract
BACKGROUND: When patients suffer from incurable cancer, drug-based, systemic anticancer therapy is usually used with the aim of longer survival, while minimizing toxicity and ensuring a tolerable quality of life. It is unclear to what extent and with what degree of success systemic tumor therapy can be used to specifically improve pre-existing pain and an already compromised quality of life (QoL). METHODS: Therefore, a systematic review of oncological therapy studies (PubMed) was conducted. Only studies that identified the pain-relieving and QoL-enhancing effects of systemic anticancer therapy as the primary endpoint were selected and evaluated descriptively. RESULTS: Of the 2229 abstracts identified using a piloted search string, only 13 studies met the inclusion criteria. Of these, 10 studies showed an improvement in QoL-parameters through the use of systemic tumor therapies. DISCUSSION: Only a few studies focused primarily on the improvement of parameters related to quality of life-although this is the primary therapeutic goal for many patients suffering from incurable and advanced cancer. The study results encourage regular inclusion of symptom- and QoL-related data in clinical studies and to more explicitly address the potential of systemic anticancer therapy in relieving pain and other symptoms, thereby supporting the goals of palliative care.
BACKGROUND: When patients suffer from incurable cancer, drug-based, systemic anticancer therapy is usually used with the aim of longer survival, while minimizing toxicity and ensuring a tolerable quality of life. It is unclear to what extent and with what degree of success systemic tumor therapy can be used to specifically improve pre-existing pain and an already compromised quality of life (QoL). METHODS: Therefore, a systematic review of oncological therapy studies (PubMed) was conducted. Only studies that identified the pain-relieving and QoL-enhancing effects of systemic anticancer therapy as the primary endpoint were selected and evaluated descriptively. RESULTS: Of the 2229 abstracts identified using a piloted search string, only 13 studies met the inclusion criteria. Of these, 10 studies showed an improvement in QoL-parameters through the use of systemic tumor therapies. DISCUSSION: Only a few studies focused primarily on the improvement of parameters related to quality of life-although this is the primary therapeutic goal for many patients suffering from incurable and advanced cancer. The study results encourage regular inclusion of symptom- and QoL-related data in clinical studies and to more explicitly address the potential of systemic anticancer therapy in relieving pain and other symptoms, thereby supporting the goals of palliative care.
Entities:
Keywords:
Pain; Quality of life; Studies; Systematic review; Tumor therapy
Authors: Helene Svensson; Zakaria Einbeigi; Hemming Johansson; Thomas Hatschek; Yvonne Brandberg Journal: Breast Cancer Res Treat Date: 2010-08-03 Impact factor: 4.872
Authors: J F Vansteenkiste; J E Vandebroek; K L Nackaerts; P Weynants; Y J Valcke; D A Verresen; R C Devogelaere; S A Marien; Y P Humblet; N L Dams Journal: Ann Oncol Date: 2001-09 Impact factor: 32.976
Authors: Edwin P Rock; Jane A Scott; Dianne L Kennedy; Rajeshwari Sridhara; Richard Pazdur; Laurie B Burke Journal: J Natl Cancer Inst Monogr Date: 2007
Authors: James Chih-Hsin Yang; Vera Hirsh; Martin Schuler; Nobuyuki Yamamoto; Kenneth J O'Byrne; Tony S K Mok; Victoria Zazulina; Mehdi Shahidi; Juliane Lungershausen; Dan Massey; Michael Palmer; Lecia V Sequist Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544